AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection

Published: 16 November 2023

Views:
1338
Likes:
7

Views:
1338
Likes:
7
Share:

Now Playing
Part 1 | Session 3 of 10
MINT: Myocardial Ischaemia & Transfusion
Nazli Okumus, Jeffrey L Carson

Up Next
11m 41s

Part 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension
George L Bakris, Sukriti Banthiya
8m 35s

Part 1 | Session 5 CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients
Hanad Bashir, William T Abraham
14m 32s

Part 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health
Ramy Doss, Chiadi E Ndumele
10m 36s

Part 1 | Session 7 AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF
Naima Maqsood, Christian Ruff
9m 14s

Part 1 | Session 8 An Extended Duration Short-Interfering RNA Targeting Lp(a)
Maryam Barkhordarian, Steven E Nissen
11m 15s

Part 1 | Session 9 ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin
Naima Maqsood, Jeff Healey
15m 26s

Part 1 | Session 10 ARIES HM3: Avoidance of Aspirin with LVAD Devices
Mandeep Mehra, Christian Inchaustegui

14m 58s

Part 1 | Session 1 ORBITA-2: PCI for Stable Angina Rasha Al-Lamee, Nazli Okumus, Christopher Rajkumar

11m 47s

Part 1 | Session 2 SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients A Michael Lincoff , Ahmed Ghoneem

Average (ratings)

No ratings

Your rating

Overview

In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.

These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

More from this programme

Part 1

Radcliffe & Cardionerds @AHA23

10 sessions
ORBITA-2: PCI for Stable Angina	Watch now
SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients	Watch now
MINT: Myocardial Ischaemia & Transfusion	Watch now
KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension	Watch now
CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients	Watch now
AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health	Watch now
AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF	Watch now
An Extended Duration Short-Interfering RNA Targeting Lp(a)	Watch now
ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin	Watch now
ARIES HM3: Avoidance of Aspirin with LVAD Devices	Watch now

About the episode

AHA 2023 — Investigator, Dr Jeffrey Carson (Rutgers University, US) joined Dr Nazli Okumus, CardioNerds Ambassador to discuss findings from the MINT trial (NCT02981407).

The aim of this randomised, parallel assignment trial (Rutgers) is to compare liberal and restrictive red blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anemic. Investigators enrolled 3,506 patients with AMI and a hemoglobin level less than 10 g/dL at 144 centers in the United States, Canada, France, Brazil, New Zealand and Australia. Patients will be randomized to either a liberal or restrictive transfusion strategy. The primary endpoint is a composite of all-cause death or recurrent MI within 30 days following randomization.

Findings presented at AHA showed that the MINT trial did not demonstrate a statistically significant recurrence in the rate of 30-day death or recurrent MI in patients with acute MI and anaemia assigned to a restrictive transfusion strategy as compared to a liberal strategy. While not statistically significant, point estimates for the primary outcome and secondary outcomes consistently favoured a liberal transfusion strategy.

Recorded on-site at AHA 2023, Philadelphia.

Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

Faculty Biographies

Nazli Okumus

Dr. Nazli Okumus is currently in her third year as a Cardiology Fellow at Allegheny Health Network (AHN) in Pittsburgh, PA, where she is dedicated to advancing her training in interventional cardiology. She successfully completed her residency at Case Western MetroHealth in Cleveland, OH. Her commitments extend to serving as a member of the SCAI Political Action Committee, contributing to the ACC FIT Editorial Fellowship program Advocacy section, and acting as the CardioNerds Ambassador, representing her fellowship program while participating in the CardioNerds IC and CCC committees. In addition, she is actively engaged in digital education and mentorship, with a particular emphasis on empowering women in medicine. Her research and clinical interests encompass cardiogenic shock, valvular heart disease, and complex coronary interventions. Dr. Okumus is fervently committed to patient advocacy and addressing health disparities.